CLARITY-Gastric 02: a randomised Phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma (GC / GEJC / EAC)

sonesitatug vedotin (AZD0901) - AstraZeneca

rilvegostomig (AZD2936) - AstraZeneca

capecitabine - Generic mfg.

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/print/presentation/820

Kohei Shitara; Lin Shen; Salah-Eddin Al-Batran; Jeeyun Lee; Elizabeth Smyth; Filippo Pietrantonio; Maria Ignez Braghiroli; Xiaotian Zhang; Bingying Xie; Marielle Holmblad; Silver Liu; Yelena Y. Janjigian

Jul 17, 2026